Najmul Hasan Forhad: VWF Concentrates in Modern Hematology and Transfusion Medicine
Najmul Hasan Forhad, Medical Laboratory Technician at Doctors Without Borders, shared on LinkedIn:
”Topic : Immunohematology and Hemostasis
von Willebrand factor (vWF) concentrates is essential in both clinical practice and laboratory medicine, especially when managing patients with von Willebrand disease (vWD) and certain cases of hemophilia A.
Several therapeutic products are commonly used in replacement therapy, including Alphanate, Humate P, Wilate, and recombinant von Willebrand factor preparations.
Alphanate and Humate P are plasma-derived concentrates containing both vWF and factor VIII, providing effective hemostatic support in patients with bleeding disorders.
Humate P is particularly recognized for its predictable vWF:FVIII ratio and is widely used in surgical prophylaxis and severe bleeding management.
Wilate is another plasma-derived product that is highly purified and formulated to closely resemble the physiologic balance between vWF and factor VIII.
It is commonly used for both acute treatment and prophylactic therapy.
Recombinant von Willebrand factor products represent an important advancement in transfusion medicine and hematology.
Because they are not plasma-derived, they minimize the risk of blood-borne pathogen transmission and offer a more targeted therapeutic approach.
From an educational and examination perspective, understanding the differences between plasma-derived and recombinant products, their clinical indications, and their role in different subtypes of vWD remains highly important for laboratory professionals and healthcare practitioners.
Clinical laboratory science continues to play a critical role in bridging diagnostic hematology with evidence-based patient management.”
Stay updated with Hemostasis Today.
-
Aug 19, 2026, 01:43Elvira Grandone: Cancer and Thrombosis in Women – Where Do We Stand?
-
Aug 19, 2026, 01:37Ifeanyichukwu Ifechidere: Coagulation Knowledge – A Core Skill in Internal Medicine
-
Aug 19, 2026, 01:34Tommy Alfaro Moya: Celebrating a New Chapter Contribution in Clinical Hematology and Hemato-Oncology
-
Aug 19, 2026, 01:29Axay Tomar: Precision Transfusion and Optimizing Blood Component Therapy in Hematology
-
Aug 19, 2026, 01:21Navigating the Unpredictability of Factor VII Deficiency – EHC
-
Aug 18, 2026, 19:49Make the Most of Your Summer and Catch Up on Gene Therapy – EAHAD
-
Aug 18, 2026, 19:46Lesley Van Wyk: ANA Testing – From Screening to Interpretation
-
Aug 18, 2026, 19:45Factor IV – The ‘Coagulation Factor’ That Isn’t a Protein – ICHCC
-
Aug 18, 2026, 19:42Melanie Jay: What Should Behavioral Support Look Like Alongside Obesity Medications?